The Modern Data Company Launches Dex, Conversational AI That Knows When It Has the Answer and Admits When It Doesn’t 
Keeping the Business Running While IT Recovers: A Practical Continuity Guide 
Helport AI Advances Transition to Autonomous AI Labor in Southeast Asian Fintech Market New CyberVadis report pits expectation against reality in third party risk assessments
Study compares security measures publicly declared by organisations with evidence-based assessments through the CyberVadis platform…
Netacea Index Identifies Top Five Scalper Bot Targets: Graphics Cards, Sneakers Lead List
New quarterly report reveals most in-demand goods bought for resale using automated bots Manchester, UK…
Tiziana Life Sciences plc: PDMR Dealing
LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq:…
Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215
Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of the Polθ…
MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis
GHENT, Belgium, Sept. 28, 2021 (GLOBE NEWSWIRE) — MRM Health, a biopharmaceutical company developing next-generation…
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate High…
Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)
REGULATED INFORMATION Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines,…
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Saint-Herblain (France) and New York (United States), September 28, 2021 – Valneva SE (Nasdaq: VALN;…
22nd Century to Participate in September and October 2021 Investor Conferences
BUFFALO, N.Y., Sept. 27, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
— Additional ~$19M Funding for Expanded Anthrax PEP Development Program — BARDA Contract Now Valued…
NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series
Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the,…
Novozymes is unlocking growth with the ambition of doubling company revenue by 2030
With the launch of “Unlocking Growth – Powered by Biotech” Novozymes presents its 2025-strategy. It…
Novozymes announces its 2025 strategy: Unlocking growth – powered by biotech
Please read the full announcement in PDF Attachment 2021_46_Novozymes_announces_ 2025_strategy
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced…
Tiziana Life Sciences Plc – Results of Court Meeting and General Meeting
LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) — On 20 August 2021, Tiziana Life Sciences Plc…
OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
NANTES, France, Sept. 27, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today…
Accelus to Showcase Its Enabling Technologies at the Upcoming 36th Annual North American Spine Society Meeting in Boston
PALM BEACH GARDENS, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) — Accelus, a privately held medical…
Skye Bioscience Announces $7.0 Million Registered Direct Offering
SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…